When it comes to biotech’s performance over the last several weeks, the author of today’s article notes that “Part of the sector’s rise is undoubtedly attributed to the work toward developing a coronavirus vaccine yet biotech has also become a safe haven of sorts where worried investors park their money during uncertain times.” Against this backdrop, he highlights four biotech stocks that investors may want to pay particularly close attention to. For more, CLICK HERE.
The niche market segment that’s been dominating the attention of active traders over the last several weeks? Biotechnology! So where is biotech likely headed from here? Today’s article looks to provide an answer to this question by looking “at several charts from across the sector and try[ing] to determine how followers of technical analysis will be positioning themselves over the weeks and months ahead.” For more, CLICK HERE.
When it comes to the top biotech stocks to consider buying this month, as identified in today’s article, one has a virtual monopoly in its market and lots of cash. Another doesn’t have a monopoly, doesn’t have lots of cash, and doesn’t even have an approved drug on the market yet! What this small biotech does have, however, “is tremendous growth potential and at least one possible game-changer in its pipeline” – and while it’s the riskiest of the three stocks, it could also be the biggest winner. For more, CLICK HERE.
There is currently only one drug that has demonstrated the potential to be a safe and effective treatment for COVID-19 in clinical trials: Gilead Sciences’ remdesivir. Today’s article, however, highlights a small, under-the-radar biotech with an experimental drug that has shown early promise in fighting COVID-19 when used in combination with remdesivir, reducing the replication of the novel coronavirus to “undetectable levels”. Could this biotech piggyback on Gilead’s success with remdesivir, creating a big opportunity for investors? CLICK HERE.
When it comes to low-priced (under-$10) stocks, the author of today’s article acknowledges that “These types of equities…tend to be exceptionally risky and highly volatile from a price standpoint.” But he also points out some significant upsides to buying low-priced stocks, including the fact that they can, on occasion, “deliver substantial returns on capital within an exceedingly short period.” With this in mind, he proceeds to highlight what may be two of the top stocks under $10 right now: a pair of biotech stocks that seemingly remain undervalued despite heating up in recent weeks. For more, CLICK HERE.
FDA approval is the ultimate prize in the biotech industry – and one of the few major catalysts for biotech stocks. As a result, having just received FDA approval for key products, the two biotech stocks highlighted in today’s article have made their way onto Wall Street’s radar – and may be compelling biotech picks. For these two biotech stocks, CLICK HERE.
“In light of the ongoing COVID-19 pandemic, a number of pharma companies have postponed new study starts and have paused enrollment/screening in their clinical trials. However, companies that have completed an analysis of their trial data are sticking to the timeline of reporting the results,” notes the author of today’s article, who proceeds to take a look at three biotech/pharma companies that are still expected to report clinical trial results this quarter. For these three companies – and their potential catalysts due this quarter – CLICK HERE.
While the five biotech stocks highlighted in today’s article are a mix of large-cap leaders in the space and small-cap companies with massive upside potential, they are all best suited for aggressive growth accounts with a higher risk tolerance. For these five biotech stocks that have been identified by RBC as top picks – including one firm with a potential coronavirus treatment and other firms that RBC believes have “gigantic upside” beyond coronavirus – CLICK HERE.
As the number of cases of infection by the novel coronavirus around the world rises, so are shares of a number of biotech companies with exposure to experimental vaccines (as was the case a few years back during the Ebola crisis). For four such biotech stocks – two of which are up over 250% since the beginning of the year – CLICK HERE.
In response to the spread of the new Chinese coronavirus – including its reaching the U.S. – U.S. stocks initially tumbled before rebounding as investors focused on positive earnings news. With more bad news and fear concerning the virus likely on the way, what will the virus’s impact be on the stock market? Today’s article provides a comprehensive look at the virus’s impact on Chinese stocks, China-exposed retailers, travel and gaming stocks, and biotech stocks – as well as what history suggests is coming next, potential buying opportunities from coronavirus-triggered selloffs and more. CLICK HERE.